Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Fresenius Medical Care ( (FMS) ).
Fresenius Medical Care, the world’s leading provider of dialysis products and services, operates 3,601 clinics treating roughly 292,000 renal patients and manufactures core dialysis equipment such as machines and dialyzers. The company is listed in Frankfurt and New York, giving it a strong international capital markets presence and cementing its role as a central player in global renal care.
On February 24, 2026, Fresenius Medical Care announced it had filed its Annual Report on Form 20-F for fiscal year 2025 with the U.S. Securities and Exchange Commission. The filing, which includes audited consolidated financial statements and is accessible via the company’s and the SEC’s websites, enhances transparency for investors and analysts and underscores the group’s compliance with U.S. reporting standards.
The most recent analyst rating on (FMS) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Fresenius Medical Care stock, see the FMS Stock Forecast page.
Spark’s Take on FMS Stock
According to Spark, TipRanks’ AI Analyst, FMS is a Neutral.
Fresenius Medical Care’s overall score is driven by strong earnings call performance and fair valuation, offset by technical analysis indicating bearish trends and financial performance challenges. The company’s strategic initiatives and share buyback program are positive, but operational and market challenges remain.
To see Spark’s full report on FMS stock, click here.
More about Fresenius Medical Care
Fresenius Medical Care is a global leader in dialysis, providing products and services for patients with chronic renal diseases, a population estimated at around 4.5 million worldwide. Through a network of 3,601 dialysis clinics, the company treats approximately 292,000 patients and supplies key dialysis products, including machines and dialyzers, with listings on the Frankfurt and New York stock exchanges.
The group’s business model spans both direct patient care and the manufacture of dialysis equipment, positioning it at the center of the renal care value chain. Its dual listing in Europe and the U.S. underpins broad access to global capital markets and a diversified investor base, reinforcing its role as a major healthcare provider in the renal segment.
Average Trading Volume: 566,699
Technical Sentiment Signal: Buy
Current Market Cap: $13.8B
See more insights into FMS stock on TipRanks’ Stock Analysis page.